Currently, the identification of viral RNA by RT-PCR is regarded as the gold standard for COVID-19 diagnosis and treatment follow-up (
61). The detection of this pathogenic virus in respiratory specimens requires isolating the genetic material of the virus (RNA) followed by its conversion to cDNA and finally cDNA amplification. In this process, specific primers (forward and reverse) are used to amplify the target gene(s). The two most common targets are the ORF1ab and "N" genes, both of which are positive reference genes (
61,
62) (
Figure 3). The amplification condition can be set as follows: 50°C for 15 min, 95°C for 3 min, and then 45 cycles of 95°C for 15 s and 60°C for 30 seconds (
59,
62). Usually, fluorescence acquisition in qPCR with dsDNA binding dyes occurs during the melting process at a temperature between the melting points of primers and the amplicon (
63). The fluorophore-quencher probe is cleaved during thermocycler senses the fluorescent signal and tracks amplification progression in real-time (
64). The diagnostic algorithm used to detect SARS-CoV-2, the causative agent of COVID-9, uses an initial screening to detect the presence of SARS-CoV-1, SARS-CoV-2, and other viruses belonging to the
Sarbecovirus subgenus. For confirming the diagnosis, probes, and primers unique to the RdRP gene (RNA-dependent polymerase RNA) are used. Many labs in the world use the diagnostic algorithm and reagents employed by Corman et al. (
37) in Cuba, as well as their interpretation to detect SARS-CoV-2 (
37). For the "E" gene, a sample is considered positive if Ct is ≤ 36. In these cases, the diagnosis is confirmed using the RdRP gene, whose positivity is warranted at a Ct of ≤ 40. According to a report from a hospital in Wuhan, China, positive results were obtained for a patient only when both target genes (ORF1ab and N) were assessed (
62). Accordingly, the result was considered positive when the Ct value was < 37 and negative when Ct was ≥ 40. A moderate viral load, defined as a Ct value from 37 to < 40, needed re-testing for confirmation (
61). For widespread use of these molecular technologies in armed forces, military scientists must focus on designing a portable RT-PCR-based technology that is capable of integrating all procedures in one device and detecting infectious agents at affordable costs.
Figure 3 shows the target genes (Orf1ab, "E", and "N") used for the diagnosis of COVID-19 applying specific forward and reverse primers. These genes are then amplified via RT-PCR to produce a million copies of them. The presence of the genes generates signals that are detected by the RT-PCR device, confirming the diagnosis of COVID-19.